<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty-three patients, aged 3-29 years, with the following <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epileptic</z:e> types: symptomatic forehead (15), symptomatic temporal (6), symptomatic occipital (2), juvenile myoclonic, in combination with eyelid <z:hpo ids='HP_0001336'>myoclonus</z:hpo> syndrome with absences, (5), <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> with isolated <z:hpo ids='HP_0002197'>generalized seizures</z:hpo> (3) and <z:e sem="disease" ids="C0376532" disease_type="Disease or Syndrome" abbrv="BECTS">rolandic epilepsy</z:e> (2), were treated with topamax </plain></SENT>
<SENT sid="1" pm="."><plain>A medication dose was 50-200 mg per day in children younger 12 years and 100-550 mg per day in those older 12 years and in adults </plain></SENT>
<SENT sid="2" pm="."><plain>The results obtained suggest the high efficacy and well tolerability of topamax in monotherapy of <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Therapeutic effect was achieved in 28 out of 33 patients (84.8%), i.e. <z:hpo ids='HP_0001250'>seizures</z:hpo> stopping--in 18 patients (54.5%) </plain></SENT>
<SENT sid="4" pm="."><plain>Monotherapy was mostly effective in symptomatic forehead <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e>: <z:hpo ids='HP_0001250'>seizures</z:hpo> stopped in 53.3% patients and a frequency of <z:hpo ids='HP_0001250'>seizures</z:hpo> reduced in 33.3% </plain></SENT>
<SENT sid="5" pm="."><plain>Side-effects were detected only in 18% cases, they were mostly transient and resulted in treatment withdrawal in 6% patients only </plain></SENT>
</text></document>